Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseChronic Myeloid LeukemiaSubgroupalso in pregnancyBCR-ABL negativeT315I mutationICD10C92.1-MeSHLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeSequenceAntineoplastic therapySubstanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibSubstanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibSubstanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibSubstanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibAnzahl Substanzen12 RadiotherapySupportive therapySubstanceDexamethasoneGranisetronSubstanceDexamethasoneGranisetronSubstanceDexamethasoneGranisetronSubstanceDexamethasoneGranisetronAnzahl Substanzen2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleThird line Therapy phaseTherapy intentiondisease controlRisksAlopeciaAnemia Hb below 8g/dlArthalgiaBleedingCardiotoxicityDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHeart FailureHemorrhageHyperglycemiaHypertensionHypophosphatemiaIncrease AminotransferasesIncrease in lipaseInfectionsLymphopeniaMyalgiasNeutropeniaPainPleural EffusionPneumoniaPruritusPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorBurchert ACortes JCortes JEDao KTHochhaus AKantarjian JLipton JO´Brien SPreudhomme CRéa DSaglio GDiseaseAtypische chronische myeloische Leukämie, BCR-ABL-negativChronische myeloische Leukämie, chronische Phase, Erstlinie, ECOG 0-2Chronische myeloische Leukämie, Ph+/BCR-ABL+, ErstlinieChronische myeloische Leukämie, Ph/BCR-ABL+, IFN-naivChronische myeloische Leukämie, T315I Mutation, nach mind. 1 TKIchronisch myeloische Leukämie, Ph+/BCR-ABL+, Drittlinie und höherCML in stabiler Remission, mind. 3 TKI-Therapie, CML oder Ph+/BCR+ ALL, resistent auf Dasatinib oder Nilotinib, ECOG 0-2Neudiagnostizierte, chronische myeloische Leukämie, ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile Granulozyten, ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronisch myeloische Leukämie, ECOG 0-1Ph+/BCR-ABL+ chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile GranulozytenOriginDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, PACE trialDMU Hématologie, Hôpital Saint-Louis, Paris, France, ASCEMBL trialGeorgia Cancer Center at Augusta University, Augusta, USAGerman CML-Study Group, ENDURE/CML-IX trialKnight Cancer Institute, Oregon Health and Science University, Portland, USALaboratoire d’Hématologie, Centre Hospitalier Universitaire, Lille, SPIRIT trialPrincess Margaret Cancer Centre University of TorontoThe University of Texas MD Anderson Cancer Center, Houston, TX, BELA trialUniversity of Newcastle, Newcastle, United Kingdom, IRIS InvestigatorsUniversity of Texas M.D. Anderson Cancer Center, Houston, DASISION trialUniversity of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy, ENESTnd InvestigatorsUniversitätsklinikum Jena, Jena, Germany, ASC4FIRST trialProtocols in Revision 12 protocols foundAsciminib 200, Chronic Myeloid Leukemia (PID2826 V1.0)Asciminib 40, Chronic Myeloid Leukemia (PID2144 V1.0)Asciminib 80, Chronic Myeloid Leukemia (PID2941 V1.0)Bosutinib 500, Chronic Myeloid Leukemia (PID946 V1.1)Dasatinib 100, Chronic Myeloid Leukemia (PID940 V1.0)Imatinib 400 / peginterferon alpha-2a 90, Chronic Myeloid Leukemia (PID952 V1.2)Imatinib 400, Chronic Myeloid Leukemia (PID934 V1.1)Nilotinib 300, Chronic Myeloid Leukemia (PID938 V1.2)Peginterferon alpha-2a 450, Chronic Myeloid Leukemia (PID951 V2.0)Ponatinib 45, Chronic Myeloid Leukemia (PID950 V1.0)Ropeginterferon Alfa-2b 100, Chronic Myeloid Leukemia (PID3072 V1.0)Ruxolitinib 15, Chronic Myeloid Leukemia, atypical (PID1649 V1.0)
